

Does one-time ashwagandha intake improve cognitive function?

Submission date 31/10/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 02/11/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 03/01/2023	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study arms

Ashwagandha (ASH) has long been used in the traditional Ayurvedic system of medicine to enhance memory and improve cognition. Human intervention studies have linked Ashwagandha to increased cognition in patients with early dementia or bipolar disorder, but studies in healthy populations are limited. It is currently unknown if one-time supplementation with Ashwagandha can improve cognitive performance in young healthy adults. The aim of this study is to examine the effect of acute ingestion of 400 mg of ashwagandha on executive function including general attention, sustained attention, attentional shifting, and/or working memory in young adults.

Who can participate?

Healthy men and women between the ages of 18 to 59 years

What does the study involve?

Participants will be randomly allocated to receive ASH or placebo (dummy) capsules, and then perform four cognitive function tests that assess a range of cognitive and executive function aspects.

What are the possible benefits and risks of participating?

The potential benefit of participating is an increase in executive functioning.

Where is the study run from?

Texas A&M University (USA)

When is the study starting and how long is it expected to run for?

April 2019 to November 2019.

Who is funding the study?

Specnova Inc. (USA)

Who is the main contact?

Dr Richard B. Kreider
rbkreider@tamu.edu

Contact information

Type(s)

Scientific

Contact name

Prof Richard Kreider

ORCID ID

<https://orcid.org/0000-0002-3906-1658>

Contact details

Texas A&M University
675 Kimbrough Blvd.
Building #1542
College Station, TX
United States of America
77843-4253
+1 (0)979 458 1498
rbkreider@tamu.edu

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

AcuteAshwagandha2019

Study information

Scientific Title

The effect of acute ashwagandha supplementation on cognitive function

Study objectives

Acute ashwagandha extract improves cognition.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 19/07/2019, Texas A&M University Institutional Review Board (517 Blocker Building, 155 Ireland Street, Texas A&M University, College Station, TX 778431, USA; +1 (0)979 458 4067; irb@tamu.edu), ref: IRB2019-0453D

Study design

Interventional double-blinded randomized crossover controlled trial

Primary study design

Interventional

Study type(s)

Other

Health condition(s) or problem(s) studied

Improving cognition in healthy individuals

Interventions

Subjects consumed capsules containing 400 mg of a proprietary root and leaves extract of ashwagandha (NooGandha®, Specnova, Boca Raton, FL, USA) or capsules containing 400 mg of a wheat flour placebo (Placebo) once they have completed baseline testing with 8 ounces of water. A computer generated randomization to treatment was used. Once subjects were randomized to start, they followed the counter balance progression.

Intervention Type

Supplement

Primary outcome(s)

The Psychology Experiment Building Language (PEBL) software program (Version 2.1, <http://pebl.sourceforge.net>) was used to administer four cognitive function tests that assessed a range of cognitive and executive function aspects:

1. Berg-Wisconsin Card Sorting Task test (BCST) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion
2. The Go/No-Go test (GNG) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion
3. Sternberg Task Test (STT) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion
4. Psychomotor Vigilance Task Test (PVTT) at baseline, 1, 2, 3, 4, 5 and 6 hours after ingestion

Key secondary outcome(s)

There are no secondary outcome measures

Completion date

10/11/2019

Eligibility

Key inclusion criteria

Apparently healthy males and females between the ages of 18 to 59 years were recruited to participate in the study.

All subjects were healthy and free from known:

1. Cognitive deficit conditions
2. Wheat flour allergies
3. Sleep disorders
4. Cardiovascular, metabolic, or pulmonary diseases
5. History of hypertension, migraine headaches, cardiac arrhythmias, or anxiety
6. Gastrointestinal reflux disease or ulcers

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

59 years

Sex

All

Total final enrolment

15

Key exclusion criteria

Subjects who were taking prescription medications in the month prior to the initiation of the study and/or were told by a physician to abstain or restrict caffeine and/or stimulant intake

Date of first enrolment

20/07/2019

Date of final enrolment

10/11/2019

Locations**Countries of recruitment**

United States of America

Study participating centre

Texas A&M University

675 Kimbrough Blvd

Building #1542

College Station, Texas

United States of America

77843-4253

Sponsor information

Organisation
Specnova Inc.

Funder(s)

Funder type
Industry

Funder Name
Specnova Inc.

Results and Publications

Individual participant data (IPD) sharing plan

All data generated or analyzed during this study will be included in the subsequent results publication.

IPD sharing plan summary

Published as a supplement to the results publication

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		20/09/2022	03/01/2023	Yes	No